Epigenetics in metabolic dysfunction-associated steatohepatitis

被引:0
|
作者
Zhang, Yanru [1 ,2 ]
Ding, Ruike [1 ,2 ]
Hu, Liangshuo [3 ]
Liu, Enqi [1 ,2 ]
Qu, Pengxiang [1 ,2 ]
机构
[1] Xi An Jiao Tong Univ, Lab Anim Ctr, Hlth Sci Ctr, Xian 710061, Peoples R China
[2] Minist Educ China, Key Lab Environm & Genes Related Dis, Xian 710049, Peoples R China
[3] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Hepatobiliary Surg, Xian, Shaanxi, Peoples R China
基金
中国国家自然科学基金;
关键词
MASH; Epigenetics; Liver; DNA methylation; Histone modifications; Noncoding RNA; NONALCOHOLIC STEATOHEPATITIS; HEPATIC STEATOSIS; LIPID-METABOLISM; NONCODING RNAS; LIVER; EXPRESSION; DIET; HEPATOCYTES; FIBROSIS; INJURY;
D O I
10.1016/j.cellsig.2025.111684
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Metabolic dysfunction-associated steatohepatitis (MASH) is a complex disease involving genetics, environment, and lifestyle, with the potential to progress to liver fibrosis, cirrhosis, and even hepatocellular carcinoma (HCC). Although the pathogenesis of MASH is not fully clear, increasing evidence has indicated that epigenetics plays an important role in the genesis and progression of MASH, during which, as drastic changes in metabolites, epigenetics undergo drastic changes. Roles of chromatin structure, chromatin accessibility, DNA methylation, histone modification, and non-coding RNAs were considered as bridges of pathogenic factors and MASH. In this review, the research progress on the epigenetics of MASH was summarized, and indepth research and therapeutic strategies based on epigenetics is expected to bring new hope to MASH patients.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] Performance of MAST, FAST, and MEFIB in predicting metabolic dysfunction-associated steatohepatitis
    Qi, Shi
    Wei, Xiaodie
    Zhao, Jinhan
    Wei, Xinhuan
    Guo, Haiqing
    Hu, Jingxian
    Wuyun, Qiqige
    Pan, Calvin Q.
    Zhang, Nengwei
    Zhang, Jing
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2024, 39 (08) : 1656 - 1662
  • [42] Metabolic issues in patients with metabolic dysfunction-associated steatohepatitis (MASH) and their impact on MASH recurrence following liver transplantation: A narrative review
    Alnimer, Lynna
    Arellano, Diego
    Brombosz, Elizabeth
    Noureddin, Mazen
    LIVER TRANSPLANTATION, 2024,
  • [43] Prevalence and risk factors associated with metabolic dysfunction-associated steatohepatitis in patients with Helicobacter pylori infection: A population-based study
    Abdel-Razeq, Rashid
    Bitar, Lynn
    Bitar, Elio R.
    Onwuzo, Chidera
    Abu-Hammour, Mohamad-Noor
    Eren, Barish
    Mohamed, Islam
    Johnson, Adejoke
    Boustany, Antoine
    Onwuzo, Somtochukwu
    Asaad, Imad
    WORLD JOURNAL OF HEPATOLOGY, 2024, 16 (10) : 1169 - 1176
  • [44] Gut Microbiome and Hepatic Transcriptomic Determinants of HCC Development in Mice with Metabolic Dysfunction-Associated Steatohepatitis
    Dolapchiev, Lillian, I
    Gonzales, Kristyn A.
    Cruz, Lorenzo R.
    Gagea, Mihai
    Stevenson, Heather L.
    Kwan, Suet-Ying
    Beretta, Laura
    JOURNAL OF HEPATOCELLULAR CARCINOMA, 2024, 11 : 1891 - 1905
  • [45] Cardiovascular disease in patients with metabolic dysfunction-associated steatohepatitis compared with metabolic dysfunction-associated steatotic liver disease and other liver diseases: A systematic review
    Sanyal, Arun J.
    Husain, Mansoor
    Diab, Crystel
    Mangla, Kamal Kant
    Shoeb, Ahsan
    Lingvay, Ildiko
    Tapper, Elliot B.
    AMERICAN HEART JOURNAL PLUS: CARDIOLOGY RESEARCH AND PRACTICE, 2024, 41
  • [46] Treating metabolic dysfunction-associated steatohepatitis: The fat-trimming FGF21 approach
    Li, Xiaokun
    Rao, Zhiheng
    Hu, Wenhao
    Lu, Weiqin
    Luo, Yongde
    OBESITY REVIEWS, 2025, 26 (03)
  • [47] Hepatic glucose production rises with the histological severity of metabolic dysfunction-associated steatohepatitis
    Sabatini, Silvia
    Sen, Partho
    Carli, Fabrizia
    Pezzica, Samantha
    Rosso, Chiara
    Lembo, Erminia
    Verrastro, Ornella
    Daly, Ann
    Govaere, Olivier
    Cockell, Simon
    Hyotylainen, Tuulia
    Mingrone, Geltrude
    Bugianesi, Elisabetta
    Anstee, Quentin M.
    Oresic, Matej
    Gastaldelli, Amalia
    CELL REPORTS MEDICINE, 2024, 5 (11)
  • [48] Evaluation of Gremlin-1 as a therapeutic target in metabolic dysfunction-associated steatohepatitis
    Horn, Paul
    Norlin, Jenny
    Almholt, Kasper
    Viuff, Birgitte M.
    Galsgaard, Elisabeth D.
    Hald, Andreas
    Zosel, Franziska
    Demuth, Helle
    Poulsen, Svend
    Norby, Peder L.
    Rasch, Morten G.
    Vyberg, Mogens
    Fleckner, Jan
    Werge, Mikkel Parsberg
    Gluud, Lise Lotte
    Rink, Marco R.
    Shepherd, Emma
    Northall, Ellie
    Lalor, Patricia F.
    Weston, Chris J.
    Fog- Tonnesen, Morten
    Newsome, Philip N.
    ELIFE, 2024, 13
  • [49] Environmental toxicants modulate disease severity in pediatric metabolic dysfunction-associated steatohepatitis
    Jain, Ajay K.
    Busgang, Stefanie A.
    Gennings, Chris
    Yates, Katherine P.
    Schwimmer, Jeffrey B.
    Rosenthal, Philip
    Murray, Karen F.
    Molleston, Jean P.
    Scheimann, Ann
    Xanthakos, Stavra A.
    Behling, Cynthia A.
    Carpenter, Danielle
    Fishbein, Mark
    Neuschwander-Tetri, Brent A.
    Tonasia, James
    Vos, Miriam B.
    JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2024, 79 (05) : 943 - 953
  • [50] Potential utility of <sc>l</sc>-carnitine for preventing liver tumors derived from metabolic dysfunction-associated steatohepatitis
    Lyu, Junyan
    Okada, Hikari
    Sunagozaka, Hajime
    Kawaguchi, Kazunori
    Shimakami, Tetsuro
    Nio, Kouki
    Murai, Kazuhisa
    Shirasaki, Takayoshi
    Yoshida, Mika
    Arai, Kuniaki
    Yamashita, Tatsuya
    Tanaka, Takuji
    Harada, Kenichi
    Takamura, Toshinari
    Kaneko, Shuichi
    Yamashita, Taro
    Honda, Masao
    HEPATOLOGY COMMUNICATIONS, 2024, 8 (05)